Preclinical animal models to evaluate therapeutic antiviral antibodies

Despite the availability of effective preventative vaccines and potent small-molecule antiviral drugs, effective non-toxic prophylactic and therapeutic measures are still lacking for many viruses. The use of monoclonal and polyclonal antibodies in an antiviral context could fill this gap and provide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research 2024-05, Vol.225, p.105843-105843, Article 105843
Hauptverfasser: De Meyer, Amse, Meuleman, Philip
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 105843
container_issue
container_start_page 105843
container_title Antiviral research
container_volume 225
creator De Meyer, Amse
Meuleman, Philip
description Despite the availability of effective preventative vaccines and potent small-molecule antiviral drugs, effective non-toxic prophylactic and therapeutic measures are still lacking for many viruses. The use of monoclonal and polyclonal antibodies in an antiviral context could fill this gap and provide effective virus-specific medical interventions. In order to develop these therapeutic antibodies, preclinical animal models are of utmost importance. Due to the variability in viral pathogenesis, immunity and overall characteristics, the most representative animal model for human viral infection differs between virus species. Therefore, throughout the years researchers sought to find the ideal preclinical animal model for each virus. The most used animal models in preclinical research include rodents (mice, ferrets, …) and non-human primates (macaques, chimpanzee, ….). Currently, antibodies are tested for antiviral efficacy against a variety of viruses including different hepatitis viruses, human immunodeficiency virus (HIV), influenza viruses, respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and rabies virus. This review provides an overview of the current knowledge about the preclinical animal models that are used for the evaluation of therapeutic antibodies for the abovementioned viruses.
doi_str_mv 10.1016/j.antiviral.2024.105843
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3022567948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354224000512</els_id><sourcerecordid>3022567948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-5a365cedbe8cada919db80fc932bdb3f23cd9341ef6bb78f4eb2891f1762abc73</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwC5AlmxQ_8rCXVUUBqRIsYG35MRGunKTYSSX-HpeWblnNyDrjq3sQuiN4TjCpHjZz1Q1u54Lyc4ppkV5LXrAzNCW8prnAojpH00RWOSsLOkFXMW4wxlUt-CWaMF4WHFM6Rau3AMa7zhnlM9W5No22t-BjNvQZ7JQf1QDZ8AlBbWEcnMlOyb-b7q2DeI0uGuUj3BznDH2sHt-Xz_n69elluVjnhpF6yEvFqtKA1cCNskoQYTXHjRGMaqtZQ5mxghUEmkrrmjcFaMoFaUhdUaVNzWbo_vDvNvRfI8RBti4a8F510I9RslSqTCULntD6gJrQxxigkduQ6oVvSbDcS5Qbeaoi9xLlQWK6vD2GjLoFe7r7s5aAxQFImmDnIMhoHHSpmEs2B2l792_IDxDMiT4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3022567948</pqid></control><display><type>article</type><title>Preclinical animal models to evaluate therapeutic antiviral antibodies</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>De Meyer, Amse ; Meuleman, Philip</creator><creatorcontrib>De Meyer, Amse ; Meuleman, Philip</creatorcontrib><description>Despite the availability of effective preventative vaccines and potent small-molecule antiviral drugs, effective non-toxic prophylactic and therapeutic measures are still lacking for many viruses. The use of monoclonal and polyclonal antibodies in an antiviral context could fill this gap and provide effective virus-specific medical interventions. In order to develop these therapeutic antibodies, preclinical animal models are of utmost importance. Due to the variability in viral pathogenesis, immunity and overall characteristics, the most representative animal model for human viral infection differs between virus species. Therefore, throughout the years researchers sought to find the ideal preclinical animal model for each virus. The most used animal models in preclinical research include rodents (mice, ferrets, …) and non-human primates (macaques, chimpanzee, ….). Currently, antibodies are tested for antiviral efficacy against a variety of viruses including different hepatitis viruses, human immunodeficiency virus (HIV), influenza viruses, respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and rabies virus. This review provides an overview of the current knowledge about the preclinical animal models that are used for the evaluation of therapeutic antibodies for the abovementioned viruses.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2024.105843</identifier><identifier>PMID: 38548022</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antibodies ; Antibodies, Viral ; Antiviral Agents - therapeutic use ; Disease Models, Animal ; Ferrets ; Mice ; Mouse model ; Non-human primates ; Preclinical animal model ; Respiratory Syncytial Virus, Human ; SARS-CoV-2 ; Therapeutic ; Virus</subject><ispartof>Antiviral research, 2024-05, Vol.225, p.105843-105843, Article 105843</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c317t-5a365cedbe8cada919db80fc932bdb3f23cd9341ef6bb78f4eb2891f1762abc73</cites><orcidid>0000-0002-5592-1857</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.antiviral.2024.105843$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38548022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Meyer, Amse</creatorcontrib><creatorcontrib>Meuleman, Philip</creatorcontrib><title>Preclinical animal models to evaluate therapeutic antiviral antibodies</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>Despite the availability of effective preventative vaccines and potent small-molecule antiviral drugs, effective non-toxic prophylactic and therapeutic measures are still lacking for many viruses. The use of monoclonal and polyclonal antibodies in an antiviral context could fill this gap and provide effective virus-specific medical interventions. In order to develop these therapeutic antibodies, preclinical animal models are of utmost importance. Due to the variability in viral pathogenesis, immunity and overall characteristics, the most representative animal model for human viral infection differs between virus species. Therefore, throughout the years researchers sought to find the ideal preclinical animal model for each virus. The most used animal models in preclinical research include rodents (mice, ferrets, …) and non-human primates (macaques, chimpanzee, ….). Currently, antibodies are tested for antiviral efficacy against a variety of viruses including different hepatitis viruses, human immunodeficiency virus (HIV), influenza viruses, respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and rabies virus. This review provides an overview of the current knowledge about the preclinical animal models that are used for the evaluation of therapeutic antibodies for the abovementioned viruses.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>Ferrets</subject><subject>Mice</subject><subject>Mouse model</subject><subject>Non-human primates</subject><subject>Preclinical animal model</subject><subject>Respiratory Syncytial Virus, Human</subject><subject>SARS-CoV-2</subject><subject>Therapeutic</subject><subject>Virus</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EoqXwC5AlmxQ_8rCXVUUBqRIsYG35MRGunKTYSSX-HpeWblnNyDrjq3sQuiN4TjCpHjZz1Q1u54Lyc4ppkV5LXrAzNCW8prnAojpH00RWOSsLOkFXMW4wxlUt-CWaMF4WHFM6Rau3AMa7zhnlM9W5No22t-BjNvQZ7JQf1QDZ8AlBbWEcnMlOyb-b7q2DeI0uGuUj3BznDH2sHt-Xz_n69elluVjnhpF6yEvFqtKA1cCNskoQYTXHjRGMaqtZQ5mxghUEmkrrmjcFaMoFaUhdUaVNzWbo_vDvNvRfI8RBti4a8F510I9RslSqTCULntD6gJrQxxigkduQ6oVvSbDcS5Qbeaoi9xLlQWK6vD2GjLoFe7r7s5aAxQFImmDnIMhoHHSpmEs2B2l792_IDxDMiT4</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>De Meyer, Amse</creator><creator>Meuleman, Philip</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5592-1857</orcidid></search><sort><creationdate>202405</creationdate><title>Preclinical animal models to evaluate therapeutic antiviral antibodies</title><author>De Meyer, Amse ; Meuleman, Philip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-5a365cedbe8cada919db80fc932bdb3f23cd9341ef6bb78f4eb2891f1762abc73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>Ferrets</topic><topic>Mice</topic><topic>Mouse model</topic><topic>Non-human primates</topic><topic>Preclinical animal model</topic><topic>Respiratory Syncytial Virus, Human</topic><topic>SARS-CoV-2</topic><topic>Therapeutic</topic><topic>Virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Meyer, Amse</creatorcontrib><creatorcontrib>Meuleman, Philip</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Meyer, Amse</au><au>Meuleman, Philip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preclinical animal models to evaluate therapeutic antiviral antibodies</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2024-05</date><risdate>2024</risdate><volume>225</volume><spage>105843</spage><epage>105843</epage><pages>105843-105843</pages><artnum>105843</artnum><issn>0166-3542</issn><eissn>1872-9096</eissn><abstract>Despite the availability of effective preventative vaccines and potent small-molecule antiviral drugs, effective non-toxic prophylactic and therapeutic measures are still lacking for many viruses. The use of monoclonal and polyclonal antibodies in an antiviral context could fill this gap and provide effective virus-specific medical interventions. In order to develop these therapeutic antibodies, preclinical animal models are of utmost importance. Due to the variability in viral pathogenesis, immunity and overall characteristics, the most representative animal model for human viral infection differs between virus species. Therefore, throughout the years researchers sought to find the ideal preclinical animal model for each virus. The most used animal models in preclinical research include rodents (mice, ferrets, …) and non-human primates (macaques, chimpanzee, ….). Currently, antibodies are tested for antiviral efficacy against a variety of viruses including different hepatitis viruses, human immunodeficiency virus (HIV), influenza viruses, respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and rabies virus. This review provides an overview of the current knowledge about the preclinical animal models that are used for the evaluation of therapeutic antibodies for the abovementioned viruses.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38548022</pmid><doi>10.1016/j.antiviral.2024.105843</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-5592-1857</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0166-3542
ispartof Antiviral research, 2024-05, Vol.225, p.105843-105843, Article 105843
issn 0166-3542
1872-9096
language eng
recordid cdi_proquest_miscellaneous_3022567948
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Antibodies
Antibodies, Viral
Antiviral Agents - therapeutic use
Disease Models, Animal
Ferrets
Mice
Mouse model
Non-human primates
Preclinical animal model
Respiratory Syncytial Virus, Human
SARS-CoV-2
Therapeutic
Virus
title Preclinical animal models to evaluate therapeutic antiviral antibodies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A25%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preclinical%20animal%20models%20to%20evaluate%20therapeutic%20antiviral%20antibodies&rft.jtitle=Antiviral%20research&rft.au=De%20Meyer,%20Amse&rft.date=2024-05&rft.volume=225&rft.spage=105843&rft.epage=105843&rft.pages=105843-105843&rft.artnum=105843&rft.issn=0166-3542&rft.eissn=1872-9096&rft_id=info:doi/10.1016/j.antiviral.2024.105843&rft_dat=%3Cproquest_cross%3E3022567948%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3022567948&rft_id=info:pmid/38548022&rft_els_id=S0166354224000512&rfr_iscdi=true